MarketFriction

Aurobindo Pharma Ltd

NSE AUROPHARMA · BSE 524804 · Pharmaceuticals
₹1,676.80 +0.29%
NSE close2026-10-01
52 week range1,066.80 - 1,740.00
Market cap₹97,682 Cr.
P/E25.8
Nifty 200Nifty 500Nifty Midcap 50Nifty Midcap 100Midcap 150Nifty Midcap SelectNifty PharmaNifty Healthcare Index No price band Delivery 50.4%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales7,2197,3527,5807,5677,7967,9798,3827,8688,2868,6468,8539,150
Expenses5,8465,7535,9205,9496,2306,4016,6226,2656,6086,8737,1037,271
Operating Profit1,3731,5991,6601,6181,5661,5781,7601,6031,6781,7731,7501,880
OPM %19%22%22%21%20%20%21%20%20%21%20%21%
Other Income18816314221136159135107122123117224
Interest68768911111311811598959398102
Depreciation418423354404382419444406429465479487
Profit before tax1,0761,2621,2301,3241,2071,2001,3351,2071,2761,3391,2911,515
Tax %30%26%26%31%32%30%32%32%34%32%29%32%
Net Profit7529409079188178469038248489109211,032
EPS in Rs12.9215.9815.5115.6914.0714.5615.5614.2014.6115.6715.8617.95
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales13,77214,91016,46319,56423,09924,77523,45524,85529,00231,72433,65334,935
Expenses10,57911,46912,69115,61218,24919,49719,06021,14823,17625,16426,78327,854
Operating Profit3,1933,4413,7723,9524,8495,2784,3963,7075,8266,5606,8707,081
OPM %23%23%23%20%21%21%19%15%20%21%20%20%
Other Income200115105701663,195152291366613404586
Interest25767782633057449140290457384388
Depreciation3924285586689671,0551,1271,2451,5221,6491,7781,859
Profit before tax2,7443,0613,2413,0913,7437,3443,3732,6124,3805,0665,1125,420
Tax %26%25%25%24%24%27%22%26%28%31%31%
Net Profit2,0242,3012,4232,3642,8445,3342,6471,9283,1693,4843,5033,711
EPS in Rs34.6139.2941.3640.3648.5691.0545.2032.9054.1560.0260.3464.09
Dividend Payout %7%6%6%6%6%4%20%23%8%0%7%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth9%6%11%9%
Compounded Profit Growth6%1%23%11%
Stock Price CAGR7%19%23%57%
Return on Equity14%10%11%10%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital295959595959595959595858
Reserves5,1277,2299,31311,62213,83216,76621,87124,51726,78129,78432,59537,833
Borrowings4,4515,0413,3644,7706,9675,8265,3392,8515,2866,6488,2638,073
Other Liabilities3,3033,5683,4644,4925,4146,1136,1476,2117,3798,2278,56612,232
Total Liabilities12,91015,89616,20020,94226,27128,76533,41633,63839,50544,71749,48258,196
Fixed Assets3,7064,1804,8346,5218,4759,3969,37410,53211,02414,49314,79417,407
CWIP4208481,4581,5831,6681,9863,0623,7475,3903,8694,9005,214
Investments201232463123605555919975433722521,051
Other Assets8,76510,7459,66212,52715,76816,82720,39018,36222,54925,98329,53634,525
Total Assets12,91015,89616,20020,94226,27128,76533,41633,63839,50544,71749,48258,196
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1,2371,4203,2791,9551,6514,3813,3295,0162,3872,4353,9255,526
Cash from Investing Activity-1,017-1,446-1,787-1,927-2,904-1,563597-3,211-3,971-4,242-1,866-2,630
Cash from Financing Activity93365-1,9158641,919-1,947-1,365-2,9691,814800120-1,269
Net Cash Flow313340-4248926668712,561-1,164230-1,0072,1781,628
Free Cash Flow491-1461,5947141142,9691,5032,693-323-1,0671,4082,468
CFO/OP67%67%118%70%61%106%87%143%84%72%86%107%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days10712268686468526266616677
Inventory Days239240246317304289333272275284295326
Days Payable1361461221281079710397125129117151
Cash Conversion Cycle210217191257260260282237216216244252
Working Capital Days504451502535528455664944
ROCE %27%27%25%23%18%19%18%13%9%14%14%13%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters51.84%51.84%51.84%51.80%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.88%
FIIs22.45%20.72%18.01%16.73%16.59%16.29%15.33%14.38%14.21%13.95%15.24%16.38%
DIIs18.29%20.60%23.28%24.77%25.14%25.21%26.23%26.93%27.60%27.66%25.82%25.05%
Government0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.03%0.05%0.05%
Public7.43%6.85%6.87%6.69%6.45%6.67%6.61%6.88%6.37%6.55%7.08%6.63%
No. of Shareholders2,59,6382,41,9442,44,5752,38,6222,48,4882,57,9622,69,3232,72,2082,47,6622,36,8592,41,2982,39,073

Fundamentals

Market Cap₹ 97,682 Cr.
Current Price₹ 1,698
Stock P/E25.8
Book Value₹ 652
ROCE12.9 %
ROE10.1 %
Dividend Yield0.24 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)9%
Compounded Profit Growth (TTM)11%
Consolidated figures.
Valuation
Market capRs 97,389 Cr
Enterprise valueRs 95,591 Cr
P/E (TTM)26.23x
Price to book2.57x
Price to sales2.79x
EV / EBITDA12.47x
EV / EBIT16.46x
EV / sales2.74x
Price to cash flow17.62x
Earnings yield3.81%
Dividend yield0.24%
P/E, 3-year average20.35x
P/B, 3-year average2.07x
P/E, 5-year average18.32x
P/B, 5-year average1.79x
Profitability
Operating margin (excl. other income)20.41%
Operating margin (incl. other income)21.61%
EBITDA margin21.95%
Pre-tax margin15.51%
Net profit margin10.63%
Net margin, latest quarter11.28%
ROE9.94%
ROCE12.65%
ROA6.51%
ROE, 3-year average10.76%
ROCE, 3-year average13.51%
ROA, 3-year average7.15%
ROE, 5-year average10.23%
ROCE, 5-year average12.46%
ROA, 5-year average6.92%
ROIC (approx.)11.03%
Tax rate31.47%
Other income / net worth1.07%
Growth
Sales growth (latest year)6.08%
Profit growth (latest year)0.54%
Sales CAGR, 3 years10.63%
Sales CAGR, 5 years6.32%
Profit CAGR, 3 years22.05%
Profit CAGR, 5 years-8.06%
Sales growth QoQ3.35%
Profit growth QoQ12.08%
Sales growth YoY (latest quarter)16.30%
Profit growth YoY (latest quarter)25.20%
Per share
EPS (TTM)Rs 63.92
EPS (latest year)Rs 60.34
EPS (latest quarter)Rs 17.78
EPS, 3-year averageRs 58.17
EPS, 5-year averageRs 50.52
Book value per shareRs 652.39
Sales per shareRs 601.50
Cash flow per shareRs 95.15
Free cash flow per shareRs 42.49
Dividend per share (latest year)Rs 4.00
Dividend per share, 3-year averageRs 4.25
Dividend per share, 5-year averageRs 6.25
Dividends
Dividend payout6.63%
Dividend payout, 3-year average7.47%
Dividend payout, 5-year average14.41%
Efficiency
Asset turnover0.58x
Fixed asset turnover1.93x
Inventory turnover1.33x
Inventory days274 days
Debtor days77 days
Debtors turnover4.74x
Creditor days151 days
Cash conversion cycle252 days
Working capital days44 days
Leverage
Total debtRs 8,073 Cr
Cash and bankRs 9,870 Cr
Net debtRs -1,797 Cr
Debt to equity0.21x
Net debt / EBITDA-0.23x
Interest coverage14.97x
Current ratio (filing 2026-03-31)1.81x
Quick ratio (filing 2026-03-31)1.15x
Trade payables (filing 2026-03-31)Rs 5,567 Cr
Owners' fund to total sources65.11%
Debt to assets13.87%
Cash flow
Cash from Operating Activity (latest year)Rs 5,526 Cr
Cash from Investing Activity (latest year)Rs -2,630 Cr
Cash from Financing Activity (latest year)Rs -1,269 Cr
Net Cash Flow (latest year)Rs 1,628 Cr
Free cash flow (latest year)Rs 2,468 Cr
FCFE (approx.: FCF + change in debt)Rs 2,278 Cr
Cash from ops / profit, 5 years1.31x
Sales to cash flow6.09x
Statement figures
Net sales (TTM)Rs 34,935 Cr
Net sales (latest year)Rs 33,653 Cr
Sales (latest quarter)Rs 9,150 Cr
Operating profit excl. other income (latest year)Rs 6,870 Cr
Operating profit (latest quarter)Rs 1,880 Cr
Other income (TTM)Rs 586 Cr
EBITDA (TTM)Rs 7,667 Cr
PBDT (TTM)Rs 7,279 Cr
Profit before tax (TTM)Rs 5,420 Cr
Tax (latest year)Rs 1,609 Cr
Net profit (TTM)Rs 3,713 Cr
Net profit (latest year)Rs 3,505 Cr
Net profit (latest quarter)Rs 1,033 Cr
Depreciation (TTM)Rs 1,859 Cr
Depreciation (latest quarter)Rs 487 Cr
Interest (TTM)Rs 388 Cr
Cost of goods sold (latest year)Rs 16,077 Cr
Total expenditure (latest year)Rs 26,783 Cr
Total income (latest year)Rs 34,057 Cr
Share capitalRs 58 Cr
ReservesRs 37,833 Cr
Shareholders' fundsRs 37,891 Cr
Total assetsRs 58,196 Cr
Net blockRs 17,407 Cr
Capital work in progressRs 5,214 Cr
InvestmentsRs 1,051 Cr
ReceivablesRs 7,094 Cr
InventoryRs 12,053 Cr
Other liabilitiesRs 12,232 Cr
Shares outstanding (crore)58.08
Ownership
Promoter holding51.88% (+0.06 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 26.2 is at the 88th percentile of its own 9.4-year range (median 17.6, low 5.8, high 35.7).
P/B 2.57 is at the 59th percentile (median 2.43).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodAUROPHARMANifty 50Difference
1 week-2.3%-2.8% +0.5 pts
1 month-0.4%-6.8% +6.4 pts
3 months+3.5%-7.6% +11.1 pts
6 months+28.5%+0.4% +28.1 pts
1 year+52.9%-9.9% +62.8 pts
2 years+13.2%-13.6% +26.8 pts
3 years+83.4%+14.2% +69.2 pts
5 years+133.8%+27.9% +105.9 pts
221 mutual fund schemes hold about ₹15,723 Cr. Over three months 51 bought more and 51 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
HDFC Mid Cap Fund2.12%2,291 -2%
Quant ELSS Tax Saver Fund8.49%1,142 +3%
Quant Mid Cap Fund10.45%842 -3%
SBI Large & Midcap Fund1.91%807 -11%
Quant Multi Cap Fund9.46%731 +6%
SBI Flexicap Fund2.96%688 +3%
SBI Midcap Fund2.13%522 +3%
SBI Midcap Fund2.13%518 +3%
Quant Flexi Cap Fund7.00%516 +2%
HDFC Balanced Advantage Fund0.43%464 +4%
HDFC Large & Mid Cap Fund1.22%371 +2%
Quant Large & Mid Cap Fund9.73%339 +4%
UTI Mid Cap Fund2.15%275 +1%
SBI Contra Fund0.56%269 +5%
Kotak Arbitrage Fund(M0.35%263 +43%
SBI ELSS Tax Saver Fund0.81%258 +5%
Old Bridge Focused Fund5.97%238 -11%
Bandhan Large & Mid Cap Fund1.08%227 +2%
SBI Healthcare Opp Fund3.90%226 -9%
SBI Dividend Yield Fund2.41%206 +4%
SBI MNC Fund3.06%206 -2%
Aditya Birla SL Arbitrage Fund0.68%184 +44%
Quant Aggressive Hybrid Fund8.05%174 +4%
Bandhan Value Fund1.72%172 +5%
UTI Large & Mid Cap Fund2.58%168 +0%

Red flags

F-score 5 of 8
lookRegulator order or action Regulator order or action 2026-02-19: Aurobindo Pharma Limited has informed the Exchange about orders passed by under Central Goods and Services Tax Act
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2024-03-30RPR SONS ADVISORS PVT.LTD., P.SUNEPromoter Groupother11,635,862Rs 1266.85 CrRevokation of Pledge
2024-03-26RPR SONS ADVISORS PVT.LTD., P.SUNEPromoter Groupother16,700,000Rs 1758.59 CrPledge Creation
2024-02-29PAVANKUMAR PSEmployees/Designated Employesell1,000Rs 0.10 CrMarket Sale
2024-02-27CHANDRASEKHAR REDDY KANDATIEmployees/Designated Employesell2,000Rs 0.21 CrMarket Sale
2024-02-23RPR SONS ADVISORS PVT.LTD., P.SUNEPromoter Groupother2,300,000Rs 240.07 CrRevokation of Pledge
2024-02-23RPR SONS ADVISORS PVT.LTD., P.SUNEPromoter Groupother10,050,000Rs 1049.02 CrRevokation of Pledge
2024-02-16ROOPAK SAWHNEYEmployees/Designated Employesell3,880Rs 0.39 CrMarket Sale
2024-02-15K BHARATHIOthersell35,000Rs 3.56 CrMarket Sale
2024-02-14GITA RAOEmployees/Designated Employesell1,300Rs 0.13 CrMarket Sale
2024-02-14RPR SONS ADVISORS PVT.LTD., P.SUNEPromoter Groupother13,400,000Rs 1334.77 CrPledge Creation
2024-02-13S BALA SUBRAMANYAM REDDYEmployees/Designated Employesell2,000Rs 0.21 CrMarket Sale
2024-01-18RPR SONS ADVISORS PVT.LTD., P.SUNEPromoter Groupother400,000Rs 44.99 CrRevokation of Pledge
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹9,150 Cr +16.3% vs Jun 2025. Net profit ₹1,032 Cr +25.2%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
Ipca Laboratories Ltd49,17035.817.0 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-04-17Buy Back
2025-08-08Interim Dividend - Rs 4 Per Share
2024-08-26Annual General Meeting
2024-07-30Buy Back
2024-02-20Interim Dividend - Rs 1.50 Per Share
2023-11-20Interim Dividend - Rs 3 Per Share
2023-08-22Annual General Meeting
2023-02-17Interim Dividend - Rs 3 Per Share
2022-07-27Annual General Meeting
2022-06-06Interim Dividend - Rs 4.50 Per Share
2022-02-18Interim Dividend - Rs 1.50 Per Share
2021-11-17 Interim Dividend - Rs 1.50 Per Share
2021-08-27 Interim Dividend - Rs 1.50 Per Share
2021-08-20 Annual General Meeting
2021-02-22 Interim Dividend - Rs 1.50 Per Share
2020-11-23 Interim Dividend - Rs 1.25 Per Share
2020-08-21 Annual General Meeting/Interim Dividend - Rs 1.25 Per Share
2020-02-17 Interim Dividend - Rs 1.75 Per Share
2019-11-21 Interim Dividend - Rs 1.25 Per Share
2019-08-21 Annual General Meeting
2019-02-15 Interim Dividend - Rs 1.25 Per Share
2018-11-20 Interim Dividend - Rs 1.25 Per Share
2018-08-21 Annual General Meeting
2018-02-20 Interim Dividend Re 1/- Per Share
2017-11-21 Interim Dividend Rs 1.50 Per Share
2017-08-23 Annual General Meeting
2017-06-08 Inteim Dividend Rs 1.25 Per Share
2016-11-24 Interim Dividend Rs 1.25 Per Share
2016-08-12 Annual General Meeting
2016-06-09 Interim Dividend - Re 0.70/- Per Share
2016-02-18 Interim Dividend- Re 0.70/- Per Share
2015-11-19 Interim Dividend - Re 0.60/- Per Share
2015-08-21Annual General Meeting/ Interim Dividend - Re 0.50/- Per Share (Purpose Revised)
2015-07-20Bonus 1:10.5000
2015-06-08Third Interim Dividend - Re 1/- Per Share
2015-02-16Second Interim Dividend - Rs 2.00/- Per Share
2014-08-13Annual General Meeting/Interim Dividend Rs 1.50/- Per Share (Purpose Revised)
2014-06-11Second Interim Dividend - Rs 1.75/- Per Share
2013-11-19Interim Dividend - Rs 1.25/- Per Share
2013-07-30Annual General Meeting And Dividend Re.0.50 Per Share
2013-02-18Interim Dividend Re 1 Per Share
2012-07-30Annual General Meeting And Dividend - Re.1/- Per Share
2011-07-20Annual General Meeting And Dividend Re.1/- Per Share
2011-02-10Face Value Split From Rs.5/- To Re.1/-0.2000
2010-11-11Interim Dividend - Rs 5 Per Share
2010-09-13Annual General Meeting And Dividend Rs.2/- Per Share
2010-02-05Int Div-Rs.3/- Per Share Purpose Revised
2009-12-16Agm/Div-Rs.1.50 Per Share
2009-02-05Interim Dividend - 60% Purpose Revised
2008-08-11Agm/Dividend - 65%
2007-09-14Agm/Dividend-50%
2006-09-08Agm/Dividend-30%
DateTypeWhat it says
2026-10-02General UpdatesCompletion of acquisition.
2026-10-02AcquisitionAcquisition
2026-10-01AcquisitionAcquisition
2026-09-30Press ReleaseA press release dated September 30, 2026, titled "Acrotech Biopharma Launches ADQUEY in the U.S. and Establishes Dedicated Dermatology Business".
2026-09-29General UpdatesGeneral Updates
2026-09-21Concall / analyst meetSchedule of meet
2026-09-15General UpdatesCompletion of US FDA Inspection at Unit-II of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
2026-09-15Press ReleaseA press release dated September 15, 2026, titled "Aurobindo Pharma receives USFDA Final Approval for Beclomethasone Dipropionate HFA Inhalation Aeroso...
2026-09-12AcquisitionAcquisition
2026-09-11General UpdatesCompletion of US FDA Inspection at Unit-IV of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company
2026-09-11Concall / analyst meetSchedule of meet
2026-09-11Concall / analyst meetSchedule of meet
2026-09-11Concall / analyst meetSchedule of meet
2026-09-11Concall / analyst meetSchedule of meet
2026-09-11Concall / analyst meetSchedule of meet
2026-09-01AcquisitionIncorporation of a new wholly owned subsidiary by the name of Avogent Lifesciences Private Limited in India by Apitoria Pharma Private Limited, a wh...
2026-08-31Press ReleaseA press release dated August 31, 2026, titled "Lannett Company LLC, a wholly owned step down subsidiary of the Company announces launch of generic ver...
2026-08-28General UpdatesCompletion of US FDA Inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
2026-08-28Shareholder meetingAurobindo Pharma Limited has submitted the Exchange a copy Srutinizers report of AGM held on August 27, 2026. and voting results.
2026-08-27Shareholder meetingAurobindo Pharma Limited has submitted the Proceedings of 39th Annual General Meeting held on August 27, 2026.
2026-08-25Concall / analyst meetSchedule of meet held on September 1-2, 2026 in Hong Kong
2026-08-25Concall / analyst meetSchedule of meet
2026-08-24General UpdatesCompletion of US FDA Inspection at Lannett Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA, Inc.
2026-08-21General UpdatesCompletion of US FDA Inspection at Auro Peptides Ltd, a subsidiary/business arm of the Company.
2026-08-17General UpdatesClassification of US FDA Inspection at Raleigh Plant, North Carolina, owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the Company...
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
Put / call open interest0.55
Max pain (expiry 2026-10-27)1,700
Largest call open interest at1,800
Largest put open interest at1,700
Implied volatility, at the money25.7%
Underlying at snapshot1,676.80
Open interest by strike around the price, nearest expiry. End-of-day NSE snapshot, 01-Oct-2026 15:40:00. Max pain is the strike where option buyers together would lose the most at expiry.
Trade dateShares sold short
2026-09-304,150
2026-09-2911,539
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2021-02-24NCLTAPL Research Centre Ltd (Transferor Co.1) & 5 others Transferor Companies & Aurobindo Pharma Ltd (Transferee Co.) Vs
2020-12-14NCLTAPL Research Centre Ltd (Transferor Co.1) & 5 others Transferor Companies & Aurobindo Pharma Ltd (Transferee Co.) Vs
2020-11-11NCLTAPL Research Centre Ltd (Transferor Co.1) & 5 others Transferor Companies & Aurobindo Pharma Ltd (Transferee Co.) Vs
2020-11-03NCLTAPL Research Centre Ltd (Transferor Co.1) & 5 others Transferor Companies & Aurobindo Pharma Ltd (Transferee Co.) Vs
2020-10-16NCLTAPL Research Centre Ltd (Transferor Co.1) & 5 others Transferor Companies & Aurobindo Pharma Ltd (Transferee Co.) Vs
2020-10-12NCLTAPL Research Centre Ltd (Transferor Co.1) & 5 others Transferor Companies & Aurobindo Pharma Ltd (Transferee Co.) Vs
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Aurobindo Pharma Ltd?

Aurobindo Pharma Ltd (AUROPHARMA) has a market capitalisation of Rs 97,682 Cr. at the 2026-10-01 close.

What is the P/E ratio of Aurobindo Pharma Ltd?

Aurobindo Pharma Ltd trades at a P/E of 25.8 on trailing twelve-month profit, at the 2026-10-01 close.

What were Aurobindo Pharma Ltd's latest quarterly results?

In the Jun 2026 quarter, Aurobindo Pharma Ltd sales was Rs 9,150 Cr (+16.3% vs Jun 2025) and net profit was Rs 1,032 Cr.

What is the 52-week high and low of Aurobindo Pharma Ltd?

The 52-week high is Rs 1,740.00 and the 52-week low is Rs 1,066.80.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03